$ERNA News

Ernexa Therapeutics Announces Progress In Development Of ERNA-101; Hits Multiple Milestones Ahead Of Planned IND Submission In Q3 2026 And First‑In‑Human Study Initiation

Ernexa Stock Is Jumping Today: What's Going On?

Brookline Capital Initiates Coverage On Ernexa Therapeutics with Buy Rating, Announces Price Target of $30

Ernexa Therapeutics Stock Climbs On Breakthrough Preclinical Data

Ernexa Therapeutics Announces Its Preclinical Data From Its ERNA-101 Candidate Demonstrates 100% Long-Term Survival In Syngeneic Ovarian Cancer Models

Ernexa Therapeutics Announces 1-For-25 Reverse Stock Split Effective May 4

Ernexa Therapeutics Board Votes To Enact Reverse Stock Split Of Between 1-For-10 and 1-For-25

Ernexa Therapeutics Board Votes To Enact Reverse Stock Split Of Between 1-For-10 and 1-For-25

Ernexa Therapeutics ERNA-101 Shows Durable Tumor Regression With PD-1 Blockade In Preclinical Ovarian Cancer Models; IND Submission Planned Q3 2026; First-In-Human Trial Expected Q4 2026

Ernexa Therapeutics to Participate in Virtual Investor Closing Bell Series

Why ZIM Integrated Shipping Shares Are Trading Higher By Around 38%; Here Are 20 Stocks Moving Premarket

Ernexa Therapeutics Announces Pricing of $10.5 Million Public Offering

Ernexa Therapeutics shares are trading lower. The company announced pricing of a $10.5 million public offering.

Ernexa Therapeutics Prices Registered Public Offering Of 21M Shares And Warrants At $0.50 Per Share And Accompanying Warrant

Ernexa Therapeutics Participates in Virtual Investor “What This Means” Segment Highlighting Recent Successful Pre-IND Meeting with U.S. FDA

Ernexa Therapeutics Selected as One of Only Ten Global Companies for Prestigious JETRO Japan Entry Acceleration Program

Ernexa Therapeutics Selected For Exclusive Japan Entry Acceleration Program, Advancing Cell Therapy Pipeline In Oncology and Autoimmune Disease

Ernexa Therapeutics Announces Successful Pre-IND FDA Meeting and Continues Progress Toward First-in-Human Trial in Ovarian Cancer

Ernexa Therapeutics Completes Pre‑IND Meeting With FDA, Secures Pathway To IND And First‑In‑Human Ovarian Cancer Trial In H2 2026

Ernexa Therapeutics Presents New Preclinical Data at American Society of Hematology (ASH) Annual Meeting on Lead Cell Therapy Candidate for Treatment of Ovarian Cancer